Imagine you run a shop. Your biggest customer suddenly says, "I'll charge you extra for selling in my market — unless you change how you do business." That's essentially what the United States has done to India — not once, but repeatedly over the last 18 months.
On July 24, 2026, the US imposed a fresh 10% tariff on Indian goods under Section 301 of the Trade Act of 1974. The stated reason? India hasn't done enough to ban imports of goods made using forced labour. India was one of 60 countries targeted — but the fact that a "strategic partner" got the same treatment as dozens of others tells you something important about how trade works in today's world.
Two days before that, on July 22, 2026, President Trump dropped another bombshell — a phased tariff on generic drugs: zero for two years, then 100%, and eventually 200% — designed to force pharmaceutical companies to shift manufacturing to the US. India, which supplies nearly 47% of America's generic medicines and exported drugs worth $9.7 billion to the US in FY25, is squarely in the crosshairs.
But this didn't start in July 2026. This is a story that goes back years — and to understand where we are, you need to know where we've been.